Estimating how common human papillomavirus infection is in girls and women
Studies how common high-risk HPV infection is in girls and women aged 9 to 50.
Plain-language title generated from the registry record
Registry title: Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
Key facts
- Where
- Ho, GhanaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for girls and women aged 9 to 50 years who live in the selected communities in 8 countries in South Asia and sub-Saharan Africa, to measure how common high-risk HPV infection is.
- Age
- 9 to 50 years
- Sex
- Female only
Main reasons for not taking part
- Declining consent to take part in any activity of the study
- A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, that in the investigator's opinion prevents enrolment
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 9 and 50 years old?
Source: NCT06129253, who can take part
Where in Ghana
- University of Health and Allied Sciences (UHAS)Ho, GhanaContact: Julia LynchNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- International Vaccine Institute
- Trial code
- NCT06129253
- Record updated
- 16 July 2025
- Original description
This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations to estimate the incidence of persistent HPV infection among sexually active young women. The data to fulfill the objectives will be collected through a series of Cross-Sectional Surveys (CSS) and Longitudinal Studies (LS) in all 8 countries 3 South Asian countries including Bangladesh, Pakistan, Nepal and 5 sub-Saharan African countries including Sierra Leone, Tanzania, Ghana, Zambia and DR Congo. Qualitative sub-studies (QS) will be conducted in selected countries and populations following the CSS to further understand and unpack risk factors for HPV infection as well as to explore how gender-related dynamics including perceptions of gender norms and stigma, influence HPV burden and/or create barriers that shape girls/women access to and uptake of HPV prevention, screening, and treatment services. Specific study protocols and corresponding ethical applications for the qualitative sub-studies will be developed separately.Read full original descriptionShow less
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations to estimate the incidence of persistent HPV infection among sexually active young women. The data to fulfill the objectives will be collected through a series of Cross-Sectional Surveys (CSS) and Longitudinal Studies (LS) in all 8 countries 3 South Asian countries including Bangladesh, Pakistan, Nepal and 5 sub-Saharan African countries including Sierra Leone, Tanzania, Ghana, Zambia and DR Congo. Qualitative sub-studies (QS) will be conducted in selected countries and populations following the CSS to further understand and unpack risk factors for HPV infection as well as to explore how gender-related dynamics including perceptions of gender norms and stigma, influence HPV burden and/or create barriers that shape girls/women access to and uptake of HPV prevention, screening, and treatment services. Specific study protocols and corresponding ethical applications for the qualitative sub-studies will be developed separately.
Inclusion: 9 to 50 years old (for urban and rural CSSs) at the time of enrollment; Resident in the selected community for at least the past 3 months (with the exception of pastoralists, refugees, and commercial sex workers); Able to understand the purpose of the study and study procedures; If aged 18 years or older or legally considered an emancipated minor, able and willing to provide consent to participate in the study including sample collection; If aged <18 years (and not considered an emancipated minor), supported in their participation by a parent or guardian who is able and willing to provide consent, and; If aged <18 years (and not considered an emancipated minor), able and willing to provide assent to participate in the study.
Exclusion: A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, in the opinion of the investigator, precludes enrolment in the study; Decline consent to participate any activity of the study.